Theolytics, a biotech company aimed at producing curative cancer therapies, has named Carsten Reinhardt MD PhD as its new director, it was reported on Monday.

Dr Reinhardt is an oncology and biotech expert, with experience in translational development and early and late-stage clinical trial design, progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe.

Dr Reinhardt is serving as the chief development officer and managing director of Immatics Biotechnologies GmbH. Prior to joining Immatics, he has served Micromet Inc as CMO and on the management board. He has also held the position of head of Clinical Development at Germany's Fresenius Biotech. He has also served at Hoffmann-La Roche.